Published in Int J Pharm on May 17, 2007
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev (2009) 3.17
Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure. Nature (2015) 1.08
Ultrasmall superparamagnetic iron oxide (USPIO)-based liposomes as magnetic resonance imaging probes. Int J Nanomedicine (2012) 0.98
Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer. Bioimpacts (2014) 0.85
External magnetic field-induced selective biodistribution of magnetoliposomes in mice. Nanoscale Res Lett (2012) 0.83
Liposomes Loaded with Hydrophobic Iron Oxide Nanoparticles: Suitable T₂ Contrast Agents for MRI. Int J Mol Sci (2016) 0.79
Evaluation of asymmetric immunoliposomal nanoparticles for cellular uptake. J Microencapsul (2012) 0.75
CRMP-2 induces axons in cultured hippocampal neurons. Nat Neurosci (2001) 2.70
Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathways for growth cone collapse. J Biol Chem (2000) 1.73
Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res (2001) 1.48
Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials (2001) 1.46
Partition coefficient of a surfactant between aggregates and solution: application to the micelle-vesicle transition of egg phosphatidylcholine and octyl beta-D-glucopyranoside. Biophys J (1995) 1.22
Vesicle reconstitution from lipid-detergent mixed micelles. Biochim Biophys Acta (2000) 1.17
Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. Br J Cancer (2011) 1.13
[Procalcitonin and viral meningitis: reduction of unnecessary antibiotics by measurement during an outbreak]. Arch Pediatr (2002) 1.10
In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188. Antimicrob Agents Chemother (2000) 1.03
[Tuberculosis of the pancreas and tuberculosis of the lymph nodes of the upper region of the abdomen]. Rev Med Chir Mal Foie (1966) 1.01
Exposure to interparental violence and psychosocial maladjustment in the adult life course: advocacy for early prevention. J Epidemiol Community Health (2009) 1.01
Structure of in-serum transfecting DNA-cationic lipid complexes. FEBS Lett (1997) 0.99
[Hepatic abscesses in childhood: retrospective study about 33 cases observed in New-Caledonia between 1985 and 2003]. Arch Pediatr (2004) 0.99
Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm Res (1999) 0.97
Poly(D,L-lactide) nanocapsules prepared by a solvent displacement process: influence of the composition on physicochemical and structural properties. J Pharm Sci (2000) 0.97
Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sci (1998) 0.89
Periodate oxidation of sodium alginate in water and in ethanol-water mixture: a comparative study. Carbohydr Res (2005) 0.89
Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). Pharm Res (1998) 0.88
Interactions between a macrophage cell line (J774A1) and surface-modified poly (D,L-lactide) nanocapsules bearing poly(ethylene glycol). J Drug Target (1999) 0.87
In vitro antileishmanial activity of amphotericin B loaded in poly(epsilon-caprolactone) nanospheres. J Drug Target (2002) 0.86
Study of the toxicity of a new lipid complex formulation of amphotericin B. J Antimicrob Chemother (2003) 0.86
Strategies for the design of orally bioavailable antileishmanial treatments. Int J Pharm (2013) 0.85
Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J Control Release (2000) 0.85
Reduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers. Antimicrob Agents Chemother (2001) 0.84
Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J Antimicrob Chemother (2003) 0.84
[Migration, health and access to care in Mayotte Island in 2007: lessons learned from a representative survey]. Rev Epidemiol Sante Publique (2010) 0.82
Modulation of nitric oxide production in RAW 264.7 cells by transforming growth factor-beta and interleukin-10: differential effects on free and encapsulated immunomodulator. J Leukoc Biol (1997) 0.82
Reconstitution of non-ionic monoalkyl amphiphile-cholesterol vesicles by dilution of lipids-octylglucoside mixed micelles. Chem Phys Lipids (1993) 0.80
New sterically stabilized vesicles based on nonionic surfactant, cholesterol, and poly(ethylene glycol)-cholesterol conjugates. Biophys J (1998) 0.79
Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability. Int J Pharm (2007) 0.79
Poly(D,L-lactide) nanocapsules containing non-steroidal anti-inflammatory drugs: gastrointestinal tolerance following intravenous and oral administration. Pharm Res (1995) 0.78
Shape transitions of giant liposomes induced by an anisotropic spontaneous curvature. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (2000) 0.78
The antileishmanial properties of surface-modified, primaquine-loaded nanocapsules tested against intramacrophagic Leishmania donovani amastigotes in vitro. Ann Trop Med Parasitol (2001) 0.78
Preparation and characterisation of liposomes containing mannosylated phospholipids capable of targetting drugs to macrophages. Biochim Biophys Acta (1986) 0.78
Surface decoration of catanionic vesicles with superparamagnetic iron oxide nanoparticles: a model system for triggered release under moderate temperature conditions. Phys Chem Chem Phys (2014) 0.78
Factors influencing macrophage activation by muramyl peptides: inhibition of NO synthase activity by high levels of NO. Biochim Biophys Acta (1994) 0.78
Reduction of the uptake by a macrophagic cell line of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). J Drug Target (2000) 0.78
Wound contractions, scar contractures and myofibroblasts: a classical case study. J Trauma (1978) 0.77
In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system. J Antimicrob Chemother (1996) 0.76
Skin localization of cow's milk proteins delivered by a new ready-to-use atopy patch test. Pharm Res (2005) 0.76
[Mesenteric panniculitis, retroperitoneal lipodistrophy and pancreatic diseases. Apropos of a case]. Presse Med (1968) 0.76
Preparation and characterization of nanoparticles bearing heparin or dextran covalently-linked to poly(methyl methacrylate). J Biomater Sci Polym Ed (1999) 0.76
Self-evolving microstructured systems upon enzymatic catalysis. Biochimie (1998) 0.76
Relationship between NO-synthase activity and TNF-alpha secretion in mouse macrophage lines stimulated by a muramyl peptide entrapped in nanocapsules. Int J Immunopharmacol (1997) 0.76
Formulation of shear rate sensitive multiple emulsions. J Control Release (2001) 0.75
Interactions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin B-miltefosine-loaded nanocochleates. Colloids Surf B Biointerfaces (2013) 0.75
[Long circulating nanocapsules: interest in the treatment of severe malaria with halofantrine]. Ann Pharm Fr (2003) 0.75
Preparation and characterization of dipalmitoylphosphatidylcholine liposomes containing interleukin-2. Braz J Med Biol Res (1995) 0.75
[Linezolide in paediatrics]. Arch Pediatr (2010) 0.75
Poly(rac-lactide) nanocapsules containing diclofenac: protection against muscular damage in rats. J Biomater Sci Polym Ed (2000) 0.75
A novel muramyl peptide derivative stimulates tumoricidal activity of macrophages and antibody production by B cells. FEBS Lett (1987) 0.75
Invasive Haemophilus influenzae disease of Melanesian and Caucasian children in New Caledonia. Pediatr Infect Dis J (1993) 0.75
Role of the descending pressor pathway in the conscious and pentobarbital-anesthetized dog. Am J Physiol (1978) 0.75
Thermotropic phase behavior of in vivo extracted human stratum corneum lipids. Lipids (1997) 0.75
Evaluation of the hydrophobic drug loading characteristics in nanoprecipitated amphiphilic cyclodextrin nanospheres. Pharm Dev Technol (1998) 0.75
Biodegradable nanocapsules containing a lipophilic immunomodulator: drug retention and tolerance towards macrophages in vitro. J Drug Target (1993) 0.75
[Vascular damage caused by a radiotransparent cervico-facial foreign body]. Arch Pediatr (2006) 0.75
Optimization and characterization of freeze-dried multilamellar liposomes incorporating different standardized allergen extracts. Allergy (1994) 0.75
[Digestive migraine]. Cah Med (1970) 0.75
[Dengue in New Caledonia. Study of 68 pediatric cases]. Arch Pediatr (2001) 0.75
Granulocyte colony-stimulating factor treatment of clozapine-induced agranulocytosis. Am J Psychiatry (1996) 0.75
[Perforated gastric ulcer in the child: a rare complication, a case report]. Arch Pediatr (2003) 0.75
[Managing of skin and soft tissue infections]. Arch Pediatr (2008) 0.75
Liposomal formulations for oral immunotherapy: in-vitro stability in synthetic intestinal media and in-vivo efficacy in the mouse. J Drug Target (1998) 0.75
Design of magnetic molecularly imprinted polymer nanoparticles for controlled release of doxorubicin under an alternative magnetic field in athermal conditions. Nanoscale (2015) 0.75
Improved intracellular delivery of a muramyl dipeptide analog by means of nanocapsules. Int J Immunopharmacol (1994) 0.75
[A further case of hypercalcemic encephalopathy of unusual etiology (abuse of alkaline powder)]. Rev Neurol (Paris) (1972) 0.75
Methodology for vesicle permeability study by high-performance gel exclusion chromatography. J Chromatogr B Biomed Sci Appl (1998) 0.75
Activation of macrophages to tumour cytotoxicity by bacterial products. Ann Inst Pasteur Immunol (1986) 0.75